Compare iShares MSCI China ETF (MCHI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI China ETF trades at $54.97, while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares MSCI China ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $63.98 |
52-Week Low | $50.48 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $55.2, down 3.04% over the past day. Technical indicators show a bullish overall signal with strong moving average support, while oscillators are neutral. The ETF is positioned near key support at $55. Recent news highlights China's strong export growth, particularly in AI and tech sectors, and institutional interest, though some funds have reduced holdings. A dividend of $0.36 per share is scheduled for payment in June 2026.
The outlook for MCHI is cautiously optimistic, driven by China's robust export performance and tech sector strength, but tempered by geopolitical tensions and regulatory risks. Investment opportunities include exposure to undervalued Chinese equities and AI-driven growth, while risks involve U.S.-China trade friction and potential economic slowdowns. Investors should weigh these factors against the ETF's current technical strength.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
